The Druker Laboratory at OHSU is distinguished for its work in developing molecularly-targeted, non-chemotherapy treatments of leukemia. Dr. Druker is the recipient of the 2009 Lasker-DeBakey Award for this pioneering work, which opens the door to personalized therapy for a wide range of cancers.
Current projects in collaboration between the Keller laboratory and the Druker complement ongoing childhood cancer research programs within the Druker laboratory, including that of:
Dr. Jason Glover (pediatric hematology-oncology fellow) studies the role of kinases in cell signaling of pediatric cancers. Dr. Glover's project takes the approach of using high throughput siRNA technology and small molecule inhibitor panels to understand the processes of tumor initiation, maintenance and progression. Dr. Glover's primary area of focus is the pediatric solid tumor, neuroblastoma, which is among the 5 most frequent causes of mortality in childhood cancer.
Dr. Bill Chang (Assistant Professor, pediatric hematology-oncology) is investigating novel targets for therapies in pediatric leukemias. Dr. Chang utilizes a translational approach using RNA interference technologies to screen and identify functional biochemical targets from patient samples that have the potential to be developed for therapy.
No comments:
Post a Comment